News
ATXI
0.652
+0.02%
0.000
Weekly Report: what happened at ATXI last week (1208-1212)?
Weekly Report · 3d ago
Weekly Report: what happened at ATXI last week (1201-1205)?
Weekly Report · 12/08 09:59
Weekly Report: what happened at ATXI last week (1124-1128)?
Weekly Report · 12/01 09:56
Weekly Report: what happened at ATXI last week (1117-1121)?
Weekly Report · 11/24 09:59
Avenue Therapeutics Announces 2025 Annual Meeting Date
TipRanks · 11/18 22:49
Weekly Report: what happened at ATXI last week (1110-1114)?
Weekly Report · 11/17 09:59
Avenue Therapeutics Reports Improved Financials Amid Challenges
TipRanks · 11/14 04:39
Avenue Therapeutics Sells Baergic Bio to Axsome
TipRanks · 11/12 13:37
Weekly Report: what happened at ATXI last week (1103-1107)?
Weekly Report · 11/10 09:57
Axsome Therapeutics acquires Baergic Bio from Avenue Therapeutics
Seeking Alpha · 11/06 13:50
Avenue Therapeutics announces Baergic Bio acquisition by Axsome
TipRanks · 11/06 12:57
Axsome enters agreement to obtain exclusive global rights to AZD7325
TipRanks · 11/06 12:50
Avenue Therapeutics Signs Agreement To Sell Baergic Bio Unit To Axsome Therapeutics For $0.3M Upfront Payment, $2.5M In Milestone Payments
Benzinga · 11/06 12:34
Weekly Report: what happened at ATXI last week (1027-1031)?
Weekly Report · 11/03 09:57
Weekly Report: what happened at ATXI last week (1020-1024)?
Weekly Report · 10/27 10:00
Weekly Report: what happened at ATXI last week (1013-1017)?
Weekly Report · 10/20 09:57
Weekly Report: what happened at ATXI last week (1006-1010)?
Weekly Report · 10/13 09:59
Weekly Report: what happened at ATXI last week (0929-1003)?
Weekly Report · 10/06 09:57
Weekly Report: what happened at ATXI last week (0922-0926)?
Weekly Report · 09/29 09:57
Weekly Report: what happened at ATXI last week (0915-0919)?
Weekly Report · 09/22 09:57
More
Webull provides a variety of real-time ATXI stock news. You can receive the latest news about Avenue Therapeutics Inc through multiple platforms. This information may help you make smarter investment decisions.
About ATXI
Avenue Therapeutics, Inc. is a specialty pharmaceutical company. The Company is focused on the development and commercialization of therapies for the treatment of neurologic diseases. Its product candidate, intravenous tramadol (IV tramadol) is a novel therapy in development in the United States for managing post-operative pain as an alternative to conventional narcotics. The drug is designed to use a dual mechanism of action to block a patient’s pain signal with reduced abuse potential. This unique mechanism of action includes an opioid agonist and an inhibitor of norepinephrine and serotonin re-uptake.